[Management of locally advanced prostate cancer].
Patients with locally advanced prostate cancer(PCa) are thought to be at a significant risk of death from PCa or development of distant metastases. To improve the prognosis of those patients, a variety of clinical trials with adjuvant and/or neoadjuvant therapies have been performed. In this review, we described a benefit of integrating local and systemic therapies in the management of locally advanced PCa.
Department of Urology, Graduate School of Medicine, Chiba University.
Tomohiko
T
Ichikawa
Hiroyoshi
H
Suzuki
Takashi
T
Imamoto
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant
D018931:Antineoplastic Agents, Hormonal